← Leaderboards
Luigi Xerri
Venatorx Pharmaceuticals, Inc.
$39,662,982
Attributed
$45,100,600
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.8M · FY2011–19$20M$15M$10M$5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$45,100,600 · 8
By mechanism
N01$28,225,364 · 1
R44$9,000,000 · 3
R01$6,081,236 · 1
R43$1,794,000 · 3
Top collaborators
- Christopher John Burns11 shared
- Randy Jackson1 shared
- Bin Liu1 shared
Most similar at Venatorx Pharmaceuticals, Inc.
Same institution · by research overlap
- Bin Liu$3,147,000
- Guo-Hua Chu$599,200
- Tsuyoshi Uehara$2,000,000
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalMedicalEnterobacteriaceaeInhibitor/AntagonistIn VivoBaseCephalosporinsSeriesAdvanced DevelopmentEnzymesGram-Negative BacteriaAntibioticsResistanceInfectionSepticemiaCommunity SettingHospitalsLactamsLactamaseScale UpToxicologyCanis FamiliarisMonobactamsBacterial Drug Resistance
Grant awards (31)
Advancement to IND of novel BLI for pairing with cefixime$1,000,000
R44 · FY2019 · AI · contact PI
Development of Therapeutic Medical Countermeasures$2,057,591
N01 · FY2018 · AI · contact PI
Development of Therapeutic Medical Countermeasures$1,028,797
N01 · FY2018 · AI · contact PI
Development of Therapeutic Medical Countermeasures$1,028,795
N01 · FY2018 · AI · contact PI
Advancement to IND of novel BLI for pairing with cefixime$1,000,000
R44 · FY2018 · AI · contact PI
Development of Therapeutic Medical Countermeasures$2,034,475
N01 · FY2017 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,446,843
R01 · FY2017 · AI
Development of Therapeutic Medical Countermeasures$1,017,238
N01 · FY2017 · AI · contact PI
Development of Therapeutic Medical Countermeasures$1,017,237
N01 · FY2017 · AI · contact PI
Advancement to IND of novel BLI for pairing with cefixime$1,000,000
R44 · FY2017 · AI · contact PI
Development of Therapeutic Medical Countermeasures$1,798,159
N01 · FY2016 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,446,843
R01 · FY2016 · AI
Development of Therapeutic Medical Countermeasures$899,081
N01 · FY2016 · AI · contact PI
Development of Therapeutic Medical Countermeasures$899,079
N01 · FY2016 · AI · contact PI
Development of Therapeutic Medical Countermeasures$9,361,587
N01 · FY2015 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,448,775
R01 · FY2015 · AI
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase$1,000,000
R44 · FY2015 · AI
Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND$1,000,000
R44 · FY2015 · AI · contact PI
Development of Therapeutic Medical Countermeasures$1,975,628
N01 · FY2014 · AI · contact PI
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense$1,738,775
R01 · FY2014 · AI
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase$1,000,000
R44 · FY2014 · AI
Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND$1,000,000
R44 · FY2014 · AI · contact PI
Development of Therapeutic Medical Countermeasures$5,107,697
N01 · FY2013 · AI · contact PI
Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND$1,000,000
R44 · FY2013 · AI · contact PI
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase$1,000,000
R44 · FY2013 · AI
Novel Compounds Targeting Bacterial PBPs$300,000
R43 · FY2013 · AI
Novel Compounds Targeting Bacterial PBPs$300,000
R43 · FY2012 · AI
Preserving beta-lactam utility against pathogens producing all classes of beta-la$300,000
R43 · FY2012 · AI
Novel Metallo-beta-lactamase Inhibitors$294,000
R43 · FY2012 · AI · contact PI
Novel Metallo-beta-lactamase Inhibitors$300,000
R43 · FY2011 · AI · contact PI
Preserving beta-lactam utility against pathogens producing all classes of beta-la$300,000
R43 · FY2011 · AI